---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-030190"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2026-06-25T21:22:26+00:00"
generated_at: "2026-06-25T21:24:24.390388+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vivos extends debt-to-equity conversion deadline with Streeterville to Aug 31, 2026

## Summary
- Streeterville extends timeframe for converting up to $4.5M debt into perpetual preferred and common stock to August 31, 2026.
- Conversion is contingent on Vivos raising at least $2.6M in equity; occurs dollar-for-dollar up to $4.5M.
- Extension allows Vivos to conduct planned rights offering and maintain Nasdaq listing compliance.
- Original June 5, 2026 agreement had June 15 deadline; Company needed more time to complete equity raise.
- CEO Kirk Huntsman expresses gratitude for Streeterville's cooperation and support on new strategic business model.

## SEC filing metadata
- accession: 0001493152-26-030190
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2026-06-25T21:22:26+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315226030190/0001493152-26-030190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315226030190/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-030190
- JSON: https://secwatch.observer/filing/0001493152-26-030190.json
- Plain text: https://secwatch.observer/filing/0001493152-26-030190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.